<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pimavanserin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pimavanserin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pimavanserin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="108194" href="/d/html/108194.html" rel="external">see "Pimavanserin: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F46507240"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Increased mortality in elderly patients with dementia-related psychosis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Pimavanserin is not approved for the treatment of patients with dementia who experience psychosis unless their hallucinations and delusions are related to Parkinson disease.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F46579278"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Nuplazid</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F46507243"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Second Generation (Atypical) Antipsychotic</li></ul></div>
<div class="block doa drugH1Div" id="F46731797"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="53849a3c-492c-4f9d-8368-135d764a0a0d">Parkinson disease psychosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parkinson disease psychosis:</b>
<b>Oral:</b> 34 mg once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> In general with antipsychotic therapy, gradual dose reduction is advised when possible (eg, depending on dosage forms and availability) to detect a re-emergence of symptoms and to avoid withdrawal reactions (eg, agitation, alternating feelings of warmth and chill, anxiety, diaphoresis, dyskinesias, GI symptoms, insomnia, irritability, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor, vertigo) unless discontinuation is due to significant adverse effects (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30588905','lexi-content-ref-17650054']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30588905','lexi-content-ref-17650054'])">Ref</a></span>). Due to the limited dosage forms (34 mg capsule and 10 mg tablet) it may not be possible to taper from 34 mg to discontinue.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Switching antipsychotics:</b> An optimal universal strategy for switching antipsychotic drugs has not been established. Strategies include: Cross-titration (gradually discontinuing the first antipsychotic while gradually increasing the new antipsychotic) and abrupt change (abruptly discontinuing the first antipsychotic and either increasing the new antipsychotic gradually or starting it at a treatment dose). Some experts recommend the following strategies when switching from clozapine or quetiapine to pimavanserin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30588905']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30588905'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Clozapine:</i></p>
<p style="text-indent:-2em;margin-left:8em;">≤100 mg/day: Add 34 mg pimavanserin to current dose (≤100 mg/day) of clozapine; after 6 weeks reduce clozapine dose over at least 4 weeks by 6.25 mg weekly until discontinued. If effectiveness decreases during taper, may return to previous dose level and try taper again in 1 week.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;100 mg/day: Add 34 mg pimavanserin to current dose (≤100 mg/day) of clozapine; after 6 weeks reduce clozapine dose over at least 4 weeks by 25 mg weekly until discontinued. If effectiveness decreases during taper, may return to previous dose level and try taper again in 1 week.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Quetiapine:</i></p>
<p style="text-indent:-2em;margin-left:8em;">≤100 mg/day: Add 34 mg pimavanserin to current dose (≤100 mg/day) of quetiapine; after 4 weeks reduce quetiapine dose by 50% weekly until reaching 12.5 mg, then discontinue. If effectiveness decreases during taper, may return to previous dose level and try taper again in 1 week.</p>
<p style="text-indent:-2em;margin-left:8em;">&gt;100 mg/day: Add 34 mg pimavanserin to current dose (&gt;100 mg/day) of quetiapine; after 4 weeks reduce quetiapine dose by 25% weekly until reaching 12.5 mg, then discontinue. If effectiveness decreases during taper, may return to previous dose level and try taper again in 1 week.</p></div>
<div class="block dora drugH1Div" id="F50991548"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Renal function may be estimated using the Cockcroft-Gault formula for dosage adjustment purposes.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCL ≥30 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">CrCL &lt;30 mL/minute: No dosage adjustment necessary; however, use with caution (increased exposure in patients with severe impairment).</p>
<p style="text-indent:-2em;margin-left:2em;">ESRD on dialysis: Nondialyzable (&lt;10% recovered in dialysate): No dosage adjustment necessary; however, use with caution (increased exposure in patients with severe impairment).</p></div>
<div class="block doha drugH1Div" id="F50988695"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doe drugH1Div" id="F46731860"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Avoid for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. If used, consider deprescribing attempts to assess continued need and/or lowest effective dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F46534572"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Confusion (6%), hallucination (5%), abnormal gait (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (7%), constipation (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Cardiovascular: Prolonged QT interval on ECG</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Aggressive behavior, agitation, angioedema, drowsiness, falling, skin rash, urticaria</p></div>
<div class="block coi drugH1Div" id="F46507246"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">History of hypersensitivity reaction (eg, rash, urticaria, symptoms consistent with angioedema [eg, tongue swelling, circumoral edema, throat tightness, dyspnea]) to pimavanserin or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F46731774"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving) (Hermanowicz 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">• Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; risks increase with age. Use with caution in patients at risk for aspiration pneumonia (ie, Alzheimer disease), particularly in patients &gt;75 years of age (Herzig 2017; Maddalena 2004).</p>
<p style="text-indent:-2em;margin-left:4em;">• Falls: May increase the risk for falls due to somnolence, orthostatic hypotension, and motor or sensory instability (Landi 2005; Seppala 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Orthostatic hypotension: May cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia) (Hermanowicz 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">• QT prolongation: Use is associated with QTc prolongation. Avoid use in patients with a history of cardiac arrhythmias, history of QT prolongation, concomitant use of medications that prolong the QT interval, and other circumstances that may increase the risk of torsades de pointes and/or sudden death (including symptomatic bradycardia, hypokalemia, and/or hypomagnesemia, and congenital long QT syndrome).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Dementia: Older adults with dementia-related psychosis treated with antipsychotics are at a higher risk of death compared to placebo. Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Use with caution in dementia with Lewy bodies; antipsychotics may worsen dementia symptoms, and patients with dementia with Lewy bodies are more sensitive to the extrapyramidal side effects (APA [Reus 2016]). Pimavanserin is not approved for the treatment of dementia psychosis unless hallucinations and delusions are related to Parkinson disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>
<b>Other warnings/precautions</b>:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of therapy: In general, when discontinuing antipsychotic therapy, gradually taper antipsychotics when possible (eg, depending on dosage forms and availability) to avoid physical withdrawal symptoms and rebound symptoms (Black 2018). Withdrawal symptoms may include agitation, alternating feelings of warmth and cold, anxiety, diaphoresis, dyskinesia, GI symptoms, insomnia, irritability, myalgia, paresthesia, psychosis, restlessness, rhinorrhea, tremor, and vertigo (Black 2018; Lambert 2007).</p></div>
<div class="block foc drugH1Div" id="F46579279"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as tartrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nuplazid: 34 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as tartrate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nuplazid: 10 mg</p></div>
<div class="block geq drugH1Div" id="F46579277"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F46817118"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Nuplazid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">34 mg (per each): $199.80</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Nuplazid Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $199.80</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F46731800"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> May be administered without regard to food. Capsules may be swallowed whole or entire contents emptied onto 1 tablespoonful (15 mL) of applesauce, yogurt, pudding, or liquid nutritional supplement to be used immediately without chewing; do not store for future use.</p></div>
<div class="block use drugH1Div" id="F46507245"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Parkinson disease psychosis: </b>Treatment of hallucinations and delusions associated with Parkinson disease psychosis.</p></div>
<div class="block mst drugH1Div" id="F54673860"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Antipsychotics are identified in the Beers Criteria as potentially inappropriate medications to be avoided in patients 65 years of age and older due to an increased risk of stroke and a greater rate of cognitive decline and mortality in patients with dementia. Evidence also suggests there may be an increased risk of mortality with use independent of dementia. Avoid antipsychotics for behavioral problems associated with dementia or delirium unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, antipsychotics should be used with caution in older adults due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults. Use of antipsychotics may be appropriate for labeled indications including schizophrenia, bipolar disorder, Parkinson disease psychosis, adjunctive therapy in major depressive disorder, or for short-term use as an antiemetic (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F46553934"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F46553931"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Pimavanserin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Pimavanserin.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Pimavanserin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Pimavanserin. Management: Decrease the pimavanserin dose to 10 mg daily when combined with strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: Pimavanserin may enhance the QTc-prolonging effect of Thioridazine. Thioridazine may decrease the serum concentration of Pimavanserin. <i> Risk X: Avoid combination</i></p></div>
<div class="block pri drugH1Div" id="F46731854"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were observed in some animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F46731855"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if pimavanserin is present in breast milk. According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F46731801"><span class="drugH1">Monitoring Parameters</span>
<table border="1" frame="border" rules="all">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center" colspan="3">
<p style="text-indent:0em;">
<b>Frequency of Antipsychotic Monitoring<sup>a,b</sup></b></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">Monitoring parameter</p></th>
<th align="center">
<p style="text-indent:0em;">Frequency of monitoring</p></th>
<th align="center">
<p style="text-indent:0em;">Comments</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>For all monitoring parameters, it is appropriate for check at baseline and when clinically relevant (based on symptoms or suspected adverse reactions) in addition to the timeline.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>b</sup> APA [Keepers 2020]; manufacturer's labeling.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> Risk factors for tardive dyskinesia include age &gt;55 years; females; White or African ethnicity; presence of a mood disorder, intellectual disability, or CNS injury; past or current extrapyramidal symptoms.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Adherence</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Every visit</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Blood chemistries (electrolytes, renal function, liver function, TSH)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Annually</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Correct electrolyte imbalances (hypokalemia) prior to administration; may prolong QT interval</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">CBC</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">As clinically indicated</p></td>
<td align="center">
<p style="text-indent:0em;">Check frequently during the first few months of therapy in patients with preexisting low WBC or history of drug-induced leukopenia/neutropenia</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">ECG</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">As clinically indicated</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Check after significant dose increase or new QTc prolonging medication if there are cardiac risk factors</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Fall risk</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Every visit</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Mental status and alertness</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Every visit</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Tardive dyskinesia</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Every visit; annually. Use a formalized rating scale at least annually or every 6 months if high risk<sup>c</sup></p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Vital signs (BP, orthostatics, temperature, pulse, signs of infection)</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Every visit (at least weekly during first 3 to 4 weeks of treatment); 4 weeks after dose change.</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Correct bradycardia prior to administration; may prolong QT interval</p></td></tr></tbody></table></div>
<div class="block pha drugH1Div" id="F46731777"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Pimavanserin acts as an inverse agonist and antagonist with high affinity for 5-HT<sub>2A</sub> receptors and low affinity for 5-HT<sub>2C</sub> and sigma 1 receptors; no affinity for 5-HT<sub>2B</sub>, dopaminergic (including D<sub>2</sub>), muscarinic, histaminergic, or adrenergic receptors, or to calcium channels.</p></div>
<div class="block phk drugH1Div" id="F46731786"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Initial effects may be observed within 15 days (Cummings 2014).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 2,173 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~95%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Primarily via CYP3A4 and CYP3A5; forms active N-desmethylated metabolite (AC-279)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Pimavanserin: ~57 hours; N-desmethylated metabolite: ~200 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 6 hours (median: 4 to 24 hours)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (&lt;1.5% as unchanged drug); urine (&lt;1% as unchanged drug; &lt;1% as metabolites)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F54091528"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Vanserin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Serivan</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Nuplazid</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Nuplazid</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimavanserin-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30588905">
<a name="30588905"></a>Black KJ, Nasrallah H, Isaacson S, et al. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. <i>CNS Spectr</i>. 2018;23(6):402-413. doi:10.1017/S1092852918001359<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimavanserin-drug-information/abstract-text/30588905/pubmed" id="30588905" target="_blank">30588905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24183563">
<a name="24183563"></a>Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. <i>Lancet</i>. 2014;383(9916):533-540. doi:10.1016/S0140-6736(13)62106-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimavanserin-drug-information/abstract-text/24183563/pubmed" id="24183563" target="_blank">24183563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26908168">
<a name="26908168"></a>Hermanowicz S and Hermanowicz N. The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson’s disease. <i>Expert Rev Neurother.</i> 2016;16(6):625-633.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimavanserin-drug-information/abstract-text/26908168/pubmed" id="26908168" target="_blank">26908168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29095482">
<a name="29095482"></a>Herzig SJ, LaSalvia MT, Naidus E, et al. Antipsychotics and the risk of aspiration pneumonia in individuals hospitalized for nonpsychiatric conditions: a cohort study. <i>J Am Geriatr Soc</i>. 2017;65(12):2580-2586. doi:10.1111/jgs.15066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimavanserin-drug-information/abstract-text/29095482/pubmed" id="29095482" target="_blank">29095482</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32867516">
<a name="32867516"></a>Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. <i>Am J Psychiatry</i>. 2020;177(9):868-872. doi:10.1176/appi.ajp.2020.177901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimavanserin-drug-information/abstract-text/32867516/pubmed" id="32867516" target="_blank">32867516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17650054">
<a name="17650054"></a>Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. <i>J Clin Psychiatry</i>. 2007;68(suppl 6):10-13.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimavanserin-drug-information/abstract-text/17650054/pubmed" id="17650054" target="_blank">17650054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15972615">
<a name="15972615"></a>Landi F, Onder G, Cesari M, Barillaro C, Russo A, Bernabei R; Silver Network Home Care Study Group. Psychotropic medications and risk for falls among community-dwelling frail older people: an observational study. <i>J Gerontol A Biol Sci Med Sci</i>. 2005;60(5):622-6226. doi:10.1093/gerona/60.5.622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimavanserin-drug-information/abstract-text/15972615/pubmed" id="15972615" target="_blank">15972615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15138897">
<a name="15138897"></a>Maddalena AS, Fox M, Hofmann M, Hock C. Esophageal dysfunction on psychotropic medication. A case report and literature review. <i>Pharmacopsychiatry</i>. 2004;37(3):134-138. doi:10.1055/s-2004-818993<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimavanserin-drug-information/abstract-text/15138897/pubmed" id="15138897" target="_blank">15138897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nuplazid.1">
<a name="Nuplazid.1"></a>Nuplazid capsules and tablets (34 and 10 mg pimavanserin) [prescribing information]. San Diego, CA: Acadia Pharmaceuticals Inc; September 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27133416">
<a name="27133416"></a>Reus VI, Fochtmann LJ, Eyler AE, et al. American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. First edition. <i>Am J Psychiatry.</i> 2016;173(5):543-546.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimavanserin-drug-information/abstract-text/27133416/pubmed" id="27133416" target="_blank">27133416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29402652">
<a name="29402652"></a>Seppala LJ, Wermelink AMAT, de Vries M, et al; EUGMS task and Finish group on fall-risk-increasing drugs. Fall-risk-increasing drugs: a systematic review and meta-analysis: II. Psychotropics. <i>J Am Med Dir Assoc</i>. 2018;19(4):371.e11-371.e17. doi:10.1016/j.jamda.2017.12.098<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pimavanserin-drug-information/abstract-text/29402652/pubmed" id="29402652" target="_blank">29402652</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 107981 Version 132.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
